At the 2011 American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, Phadia introduced ImmunoCAP® Molecular Allergy and demonstrated how it can help improve the diagnosis and management of food allergy.
With heightened awareness of the impact, prevalence, cost, and severity of food allergies, ImmunoCAP Molecular Allergy provides physicians and patients with information at the molecular level to aid in the diagnosis and management of food allergies.
Dennis Flannelly, Head of Marketing and Strategy for Phadia US said, “Thirteen ImmunoCAP Allergen Component tests were cleared by the US Food and Drug Administration in June 2011. Now that these tests are commercially available, we are working with our laboratory partners to extend awareness and usage of these valuable tools, which provide unprecedented insight into the allergic process for clinicians and patients. The 2011 AACC conference is our first public demonstration of ImmunoCAP Molecular Allergy since receiving FDA clearance, and we look forward to introducing this new, cutting edge technology to AACC attendees.”
Phadia also debuted its Phadia 2500 and 5000 platforms, the newest and largest of its fully automated laboratory systems. Phadia 2500 and Phadia 5000 improve efficiency and throughput, and offer shorter turn around times, as well as increased flexibility and reliability for both the ImmunoCAP (allergy) and ELiA (autoimmunity) product lines.
Source: Phadia AB
